This site uses optional cookies which are currently not set, but will be if you visit another page. Find out more about the cookies we use

orla-logo.jpg

Orla Protein Technologies awarded Innovate UK project to develop tools for use during checkpoint inhibitor drug development 27 April 2017

Orla Protein Technologies is proud to announce to have been chosen as a recipient of an Innovate UK grant for the development of proteins for use in the development of anti-cancer biopharmaceuticals. The project starting in April 2017 aims to engineer and develop five proteins for surface-application that will support development of drugs targeting immune checkpoint pathways.

> Read More

Blueberry

Blueberry Therapeutics commence Phase I/II clinical trial of lead product BB2603 25 April 2017

Blueberry Therapeutics are pleased to announce they have dosed the first patient in a Phase I/II clinical trial of BB2603 in fungal infection of the skin and nail following successful regulatory and ethics approvals.

> Read More

BPE strengthens new office with senior appointment 24 April 2017

BPE has strengthened its team in the North West with the appointment of Fiona Smith at its Daresbury base.

> Read More